Projects per year
Fingerprint Dive into the research topics where Gordon Mills is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 27 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks
Gray, J., Korkola, J., Heiser, L., Gray, J. & Mills, G.
9/10/14 → 6/30/20
Project: Research project
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers
Corless, C., Mills, G., Corless, C., Gray, J. & Thomas, G.
Project: Research project
Research Output
Comprehensive assessment of computational algorithms in predicting cancer driver mutations
Chen, H., Li, J., Wang, Y., Ng, P. K. S., Tsang, Y. H., Shaw, K. R., Mills, G. B. & Liang, H., Feb 20 2020, In : Genome biology. 21, 1, 43.Research output: Contribution to journal › Article
Open Access
Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
Berg, H. F., Ju, Z., Myrvold, M., Fasmer, K. E., Halle, M. K., Hoivik, E. A., Westin, S. N., Trovik, J., Haldorsen, I. S., Mills, G. B., Krakstad, C. & Werner, H. M. J., Jan 1 2020, (Accepted/In press) In : British Journal of Cancer.Research output: Contribution to journal › Article
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
Bollu, L. R., Shepherd, J., Zhao, D., Ma, Y., Tahaney, W., Speers, C., Mazumdar, A., Mills, G. B. & Brown, P. H., Dec 1 2020, In : npj Breast Cancer. 6, 1, 2.Research output: Contribution to journal › Article
Open Access
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
Yu, K., Lin, C. C. J., Hatcher, A., Lozzi, B., Kong, K., Huang-Hobbs, E., Cheng, Y. T., Beechar, V. B., Zhu, W., Zhang, Y., Chen, F., Mills, G. B., Mohila, C. A., Creighton, C. J., Noebels, J. L., Scott, K. L. & Deneen, B., Feb 6 2020, In : Nature. 578, 7793, p. 166-171 6 p.Research output: Contribution to journal › Article
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Lee, E. K., Tan-Wasielewski, Z., Aghajanian, C., Coleman, R. L., Curtis, J., Hirsch, M. S., Matulonis, U. A., Cantley, L. C., Mills, G. B., Doyle, L. A. & Liu, J. F., May 2020, In : Gynecologic Oncology Reports. 32, 100546.Research output: Contribution to journal › Article
Open Access